<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449800</url>
  </required_header>
  <id_info>
    <org_study_id>APTRM 2006-02</org_study_id>
    <nct_id>NCT00449800</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic of Ceftriaxone in Septic ICU Patients</brief_title>
  <acronym>PORTHOS</acronym>
  <official_title>Pharmacokinetics Variability of Ceftriaxone in Septic ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour La Promotion A Tours De La Reanimation Medicale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour La Promotion A Tours De La Reanimation Medicale</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ceftriaxone pharmacokinetics variability in intensive care unit septic patients&#xD;
&#xD;
      In intensive care units, drug dosage is often based on study made on healthy volunteers or on&#xD;
      less severe patients.&#xD;
&#xD;
      However, pharmacokinetic alterations have been described for some drugs used in intensive&#xD;
      care units.&#xD;
&#xD;
      These alterations, consequences of alteration of volume of distribution, of protein&#xD;
      concentrations, of impaired hepatic and renal functions can result in accumulation with&#xD;
      toxicity or &quot; under dosage &quot; with inefficacity.&#xD;
&#xD;
      Ceftriaxone is an antibiotic often prescribed in intensive care unit. However, despite this&#xD;
      large utilisation, very few data is available on the pharmacokinetic in intensive care unit,&#xD;
      and optimal dosage is not known.&#xD;
&#xD;
      Our objective is to develop a population pharmacokinetics model of ceftriaxone in intensive&#xD;
      care unit patients with sepsis, severe sepsis and septic shock and to identify the &quot; data &quot;&#xD;
      explaining interindividual variability of each pharmacokinetics parameter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a one centre population pharmacokinetics non interventional study. One group of 50&#xD;
      patients allows the development of the model and a second group of 20 patients will be used&#xD;
      for the validation of the model.&#xD;
&#xD;
      Septic patients treated with ceftriaxone according to standard procedure of our ICU could be&#xD;
      included before the second administration of the drug. In the development group, patients&#xD;
      will underwent five determination of serum concentration of ceftriaxone during the 24 hours&#xD;
      following the second administration. The timing of samples will be randomised in three&#xD;
      groups. A second phase of sampling will take place during the fifth day of ceftriaxone&#xD;
      therapy for sepsis and severe sepsis patients and after 48 hours catecholamine- free for&#xD;
      septic shock patients.&#xD;
&#xD;
      For the validation group, ten samples will be obtained at the same periods. This study will&#xD;
      not induce any change in the care of patients.&#xD;
&#xD;
      Samples will be centrifugated immediately after collection and conserved at - 20 °C.&#xD;
&#xD;
      Ceftriaxone will be assayed in the department of pharmacology, university of Marseille&#xD;
      France, usig HPLC method.&#xD;
&#xD;
      Pharmacokinetic analysis will used NONlinear Mixed Effects Modelling logiciel&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">March 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum drug concentration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetics parameter (plasmatic half-life, clearance, ...)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>ratio of serum drug concentration on MCI</measure>
  </primary_outcome>
  <enrollment>70</enrollment>
  <condition>Sepsis</condition>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eighteen-year or more&#xD;
&#xD;
          -  sepsis, severe sepsis or septic shock (according to Bone's criteria)&#xD;
&#xD;
          -  admission to intensive care unit&#xD;
&#xD;
          -  informed consent obtained&#xD;
&#xD;
          -  affiliation to medicare&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous haemodialysis&#xD;
&#xD;
          -  hemopathy&#xD;
&#xD;
          -  known allergy to cephalosporin&#xD;
&#xD;
          -  patients whose death is considered imminent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DENIS GAROT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>chru tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DENIS GAROT, MD</last_name>
    <phone>+33 2 47 47 38 55</phone>
    <email>garot@med.univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cenrte Hospitalier Régional Universitaire</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DENIS GAROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2007</study_first_posted>
  <last_update_submitted>March 20, 2007</last_update_submitted>
  <last_update_submitted_qc>March 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2007</last_update_posted>
  <keyword>Sepsis</keyword>
  <keyword>Ceftriaxone</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

